【摘 要】
：
目的 In the tyrosine kinase inhibitor (TKI) era, imatinib is the first-line therapy for patients with chronic myeloid leukemia (CML) in chronic or accelerated phase.Although second-generation TKIs (TKI2
【机 构】
：
Peking University People's Hospital West China H
【出 处】
：
中华医学会血液学分会第九次全国造血干细胞移植学术会议
论文部分内容阅读
目的 In the tyrosine kinase inhibitor (TKI) era, imatinib is the first-line therapy for patients with chronic myeloid leukemia (CML) in chronic or accelerated phase.Although second-generation TKIs (TKI2), including dasatinib and nilotinib, are appropriate treatment regimens for patients with disease that progressed to accelerated phase following imatinib therapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy.
其他文献
High-Risk AML/MDS----Great challenge of Transplantation allo-HSCT is a potentially curative therapy for patients with high-risk AML/MDS.Significant advances in therapeutic approaches, including the us
Proportion of elderly population (age 65 ≤)is rapidly growing in Japan Characteristics of aged HSCs Low repopulation potential Less homing Myeloid lineage bias Higher risk of malignant transformation
Currently, standard GvHD prophylaxis in matched sibling donor allogeneic hematopoietic stem cell transplant is the combination of short course methotrexate and calcineurin inhibitor including cyclospo
Immunopathogenesis of GVHD Central role of CD4+ T cells in GVHD Recent studies on Th22/IL-22 in GVHD Administration of IL-22 enhanced thymus recovery in mouse after total body irradiation.(Science 201
Leukemia remains a serious disease with high morbidity and mortality Elizabeth W,et al.CA Cancer J Clin.2014 Cornelissen JJ,et al.Blood,2007allo-HSCT is an effective treatment for leukemia Allo-HSCT t
Background During the last years, hematopoietic stem cell transplant from haploidentical donor is increasing by using the unmanipulated graft.We report an update of the results of allogeneic bone marr
Background Ph+ ALL is a high-risk subset of ALL that has an extremely poor prognosis Since the introduction of TKI to combination chemotherapy regimens, the majority of newly diagnosed Ph+ ALL patient
Background PT =PLT≤80 × 109/L,w/recovery of other cell count w/o apparent cause of thrombocytopenia Kim DH,et al.J Korean Med Sci,2006,21(1);46-51Kim DH et al.Bone Marrow Transplant,2006,37(1): 101-10
目的 GVHD iis the major complication after allogeneic BMT.VPA has been described as a HDAC inhibitor which had anti-inflammatory effects and could reduce the production of pro-inflammatory cytokines in
目的 探讨监测WT1基因对急性髓系白血病(AML)及骨髓增生异常综合征(MDS)患儿进行异基因造血干细胞移植(allo-HSCT)后的临床意义.方法 本文回顾性分析了2009年1月至2012年12月在我单位行allo-HSCT、且移植后连续监测WT1基因至少1年的36例儿童AML/MDS患者.留取移植后+30、+60、+90、+180、+270、+360天、+18月、+24月、+30月、+36月骨